Gigantische News von Helix - 500 Beiträge pro Seite

[Snaker]

Helix zeichnet Kooperation mit einen der größten Biotechlabors der Welt.
Helix Biopharma Corp - News Release
Helix and Maxx Bioscience to form pharmaceutical JV
Helix Biopharma Corp HBP
Shares issued 21,998,975 Sep 10 2002 close $ 2.15
Tuesday September 10 2002 News Release
Mr. Gerald Salvati reports
HELIX SIGNS MEMORANDUM OF INTENT WITH CHINESE PHARMACEUTICAL ...
A memorandum of intent to jointly discover, develop and commercialize new pharmaceutical products has been signed between Helix and Maxx Bioscience Holdings Ltd.
The memorandum contemplates Helix and Maxx entering into a business arrangement for the discovery, development and commercialization of new therapeutic agents arising from Helix`s and Maxx`s technologies and expertise.
Under the proposed arrangement, Helix will make available certain proprietary protein drug targets resulting from its heterodimer protein receptor research and Maxx will provide its proprietary "phytoceutical discovery" platform for the screening of chemical and traditional Chinese medicine libraries against these protein targets. It is contemplated that any therapeutic agent arising from these proposed activities would be jointly developed and subsequently commercialized by Helix in Europe and North America and by Maxx in Asia.
In addition, under this arrangement, Helix will assist Maxx in commercializing certain of its proprietary products in Europe and North America.
"Helix possesses both drug discovery technologies and regulatory experience in the North American and European markets, which will provide a synergistic opportunity for our two companies to discover and commercialize new therapeutics for a number of unmet medical needs," said Kitty Lo, chairwoman and chief executive officer of Maxx Bioscience Holdings Ltd.
"Maxx offers unique advantages as an established gateway of biotechnology collaborations between the East and West. The proposed arrangement should build on the strengths of both companies and therefore help Helix expand its drug pipeline for North America and Europe and, in addition, should increase Helix`s ability to commercialize its products in the growing pharmaceutical markets of Asia," said Jerome McElroy, chairman and president of Helix.
Maxx Bioscience Holdings Ltd.
Maxx Bioscience Holdings Ltd. (HKSE stock code: 512) is an Asian-based pharmaceutical company listed on the Hong Kong Stock Exchange. In May, 2002, Maxx formed a joint venture with the internationally recognized Shanghai Institute of Materia Medica under the Chinese Academy of Sciences to bring novel drug discoveries to global markets.
WARNING: The company relies upon litigation protection for "forward-looking" statements.

(c) Copyright 2002 Canjex Publishing Ltd. http://www.stockwatch.com

Jeder der einschätzen kann was diese Koopertion bedeutet, hortet seine Helixaktien wie einen Gral.
Mein persönliches Kursziel bis 31.12.2002 - 10,01 can$

Euer sanker

[tellmemore]

@snaker

auf die ,01 bestehe ich dann aber auch.

gruss
tmm

[Bombenleger]

@ tellmemore,

befasse Dich erstmal mit der Firma.

[TheRed]

Wie wäre es mit: News von...
statt Gigantische News von...

Gigantisch ist irgend etwas, wenn ein potentieller Blockbuster zugelassen wird etc..
Dies ist eine stink normale Kooperation, aus der in ca. 10 Jahren mal mit sehr viel Glück ein Medikament herauskommen kann. Interessant aber nicht gigantisch.


Jeder hortet seine Aktien??


Happy trading

The Red

[olli....]

trotz der news,scheint das hier aber niemanden zu interresieren seit 2 tagen wurden keine aktien gehandelt,hoffe das sich das bald ändert!

[tellmemore]

@bombenleger
nur die Ruhe. Ich beschäftige mich schon lange mit der Firma
und bin genauso überzeugt wie viele andere. Trotzdem ist es
doch gestattet das ich etwas schmunzel über das Kursziel von
10,01 €. 10 € wären bis dahin ja auch nicht schlecht oder ??

@olli
in Deutschland ist es immer noch ziemlich ruhig. Allerdings
ist der Umsatz in Toronto schon seit einiger Zeit ziemlich
hoch. Das hat zwar nicht unmittelbar etwas mit den news zu
tun könnte sich aber vielleicht weiter positiv auswirken.
Leider gibt es immer noch genug Verkäufer, die um die 2 CAN$
verkaufen, somit hilft uns derzeit auch die steigende Nachfrage
nicht weiter nach oben.

Ob wir bis Ende des Jahres bei 10 € stehen, weiss ich nicht.
Sicherlich ist wichtig, das die Aktie bekannter wird und dazu
kann uns jede News nur recht sein. Einen direkten Grund für
einen starken Anstieg kann ich im Moment nicht sehen, da Helix
zwar sehr gut arbeitet, wir aber bis zur endgültigen Marktfreigabe
noch einige Zeit warten müssen. Sensium könnte sicherlich auch dazu
beitragen das die Kurse steigen und vorallem mehr Käufer kommen.

In ein paar Jahren werden wir (hoffentlich) über diese Kurse
lachen und uns in anderen Regionen bewegen. Helix ist eben
für langfristige Anleger geeignet.

Gruss
tmm

[Snaker]

Hallo Helixfreunde,

ich muß mich ersteinmal wundern, wie Ihr die Texte lest, von 10,oo€ habe ich nichts geschrieben. 10,01can$.

So nun zum J.V. mit MAXX
Maxx gehört zu den größten Biotechfirmen im asiatischen Raum. Mir ist nicht bekannt das MAXX in seiner Firmengeschichte ein J.V. mit einer komerziellen Biotechfirma eingegangen ist. Was dann heißt: Das die SENSIUMtechn. derart gut ist, dass Firmen in der Größenordnung wie MAXX nicht auf diese Technology verzichten wollen. Wenn MAXX diese braucht, dann garantiert auch andere Pharma- und Biotechfirmen. Hier kurz noch was zu MAXX:
About the joint venture

In May 2002, MAXX signed an exclusive agreement with the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences (CAS-SIMM) for comprehensive drug research. CAS-SIMM is one of China`s most established and advanced drug discovery institutes.

The joint-venture company, MAXX MEDICA (Shanghai) Ltd, is 60% and 40% owned by MAXX and CAS-SIMM respectively.

MAXX will inject HK$140 million into the joint-venture within 2 years.

Phytoceutical Discovery Platform to generate internal pipeline products and compound library.

The joint-venture company will initially concentrate on 4 projects that develop novel drugs aimed at cancer, ulcer, Alzheimer`s disease and Schizophrenia. All of these drugs have significant market potentials. Other projects focusing on diabetes, obesity, inflammatory diseases are in development plan. The Company expects to provide sufficient financial support to develop these projects into clinical study, some of which will have quick returns.

MAXX will provide the financial platform, promote the commercialization of biotechnology inventions and assist in providing clinical studies outside of China that cater to the requirements of western developed countries. There is a possibility to further establish health centers under the joint-venture to align drug discovery and clinical study efforts.

MAXX has full access to SIMM`s research facilities as well as clinical study capabilities offered by a number of leading hospitals in Shanghai. The collaboration will be extended to include other CAS facilities and resources as well as international biotech companies

Weiters findet Ihr unter :http://www.maxxbioscience.com/

Es lohn sich hier mal zu lesen.

Euer snaker

[wtmartin]

Und schon wieder eine Meldung von Helix....

Helix BioPharma: New Canadian Patent Granted For Skin Patch
Friday September 20, 8:11 am ET


AURORA, ONTARIO--Helix BioPharma continues to build its portfolio of intellectual property with the granting of a Canadian patent covering the dermal and transdermal delivery of liposomal drug formulations in a skin patch.

"The issuance of this latest patent is part of our overall business strategy: to protect and maximize the value of our intellectual property and proactively seek licensing agreements", said Dr. Heman Chao, Helix`s Vice-President, Technology. "We believe the growth of Helix`s patent portfolio is an important component of the strength of our organization."

Helix BioPharma Corp. is a Canadian-based biopharmaceutical company focused on the development and commercialization of new drug products based on the combined expertise and capabilities of its highly skilled personnel and external collaborators. The Company is developing a number of emerging therapeutics based on its proprietary technologies and in-house product development initiatives, including the patented Biphasix(TM) injectionless drug delivery system, the Heterodimer Protein Technology and Molecular Sensing Technology.

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

[Royalflash]

Hi guys,

ich habe mich heute in diese Geschichte eingeklinkt mit der Maßgabe, dass ich, so hoffe ich, in ein paar Wochen mein Geld verdoppelt habe!

[Boersenfroschy]

Hi LEUTE,

jetzt hat Helix endlich mal eine Veröffentlichung in einem großen Medium geschafft. Der Focus vom Montag:

"Das kanadische Biotech Unternehmen Helix Biopharma (WKN 918846) geht neue Wege
bei der Verabreichung von Medikamenten. So transportiert die neu entwickelte Creme Biphasix die Wirkstoffe mittels Mikrokapseln über die Haut in die Blutbahn. Die Technologie scheint viel versprechend: US Pharmariese Schering-Plough
hat die Innovation bereits lizenziert. Unternehmensnahe Kreise erwarten noch in diesem Jahr eine Reihe positiver Meldungen. Schon bald ist mit einer Kooperationsvereinbarung aus Asien zu rechnen. Für die
Aktie spricht auch das solide
Finanzpolster der Firma. Anleger sollten wegen des eher mageren
Handels in Deutschland direkt an der Heimatbörse Toronto ordern."

Focus, vom 14.10.2002, S.207

[wtmartin]

Hallo Leute,

kennt ihr schon folgende Seite? Auf dieser werden alle Veröffentlichungen über Helix Biopharma gesammelt (mit Downloadmöglichkeit).
http://welcome.to/hbp-biotech
Schaut doch mal wieder rein, wenn ihr auf dem Laufenden bleiben wollt.

cu,

wtmartin

[olli....]

hi martin
war gerade auf deiner seite,naja aktuelle news stehen ja da nicht grad!aber die werden in denn nächsten monaten kommen und dann wird es mit dem kurs weiter nach oben gehen...

[tellmemore]

News

Helix Biopharma Corp - News Release

Helix granted molecular sensing technology patent

Helix Biopharma Corp
HBP
Shares issued 21,998,975
Oct 15 2002 close $ 2.48
Tuesday October 15 2002
News Release
Mr. Gerald Salvati reports
HELIX BIOPHARMA CORP.: NEW BIOSENSOR PATENT
GRANTED
Helix continues to build protection of its valuable intellectual
property with the granting of a patent for its molecular sensing
technology by the United States Patent Office.
This patent includes the use of this technology in biochip
applications to detect the interaction of various biomolecules,
including protein-protein interactions.
WARNING: The company relies upon litigation protection for
"forward-looking" statements.
(c) Copyright 2002 Canjex Publishing Ltd.
http://www.stockwatch.com

Heute war doch ein schöner Helix Tag. Hoffen wir auf weitere.
Gruss
tmm

[olli....]

Einer der hartnäckigsten Feinde der Menschheit ist das so genannte Human Papilloma Virus, kurz HPV. Zur umfangreichen Familie des Erregers gehören harmlose Herpesviren, aber auch die tückischen Auslöser des Gebärmutterhalskrebses. Die Medizin hat längst ein Gegenmittel entdeckt: Interferon Alpha. Doch das Virus versteckt sich in der Unterhaut, und da kommt Interferon schlecht ran: Über die Blutbahn wird das Mittel zu sehr verdünnt, über die Haut dringt es nicht tief genug ein.

Ausweg: das neue Transferverfahren von Helix Biopharma (WKN:918846). Helix hat eine Fähre für Medikamente entwickelt. Sie bringt Wirkstoffe eingehüllt in einen Mantel aus Fetten durch alle Schichten der Haut in den Organismus. Also kein neues Medikament, sondern ein neues Verabreichungsverfahren, das besonders empfindliche und komplexe Wirkstoffe ohne Schaden ans Ziel bringt. Das Verfahren befindet sich derzeit noch in der Prüfung in den USA, aber Helix hat bereits einen Optionsvertrag über die Vermarktung mit den Pharmakonzern Schering Plough (WKN:850469) abgeschlossen.

Medikamente gegen Papilloma-Viren bringen weltweit rund 6 Milliarden Euro Umsatz - das ist der erste Zielmarkt. Helix Biopharma denkt aber auch an weitere Anwendungen, zum Beispiel Insulin gegen Diabetes. Analysten sehen in Helix erhebliches Potential, immer unter der Voraussetzung, dass die offizielle Zulassung erfolgt.

[BB.]

Mensch, was sind das heute für Spielchen in Canada.
Da möchte aber einer den Kurs drücken.

[olli....]

News aus Canada

Press Release Source: Helix BioPharma Corp.


Helix To Complete Acquisition Of Minority Interest In Sensium
Tuesday December 3, 6:10 pm ET


AURORA, ONTARIO--Helix BioPharma previously announced, on October 16, 2002, its intention to acquire the 25% interest in Sensium Technologies Inc. ("Sensium") (33% on a fully diluted basis) not already owned by it, subject to regulatory approval.
ADVERTISEMENT


It has now been determined that a total of 2,430,000 common shares of Helix will be issued to the minority Sensium shareholders in exchange for their Sensium shares, on a 1 for 1 basis. These shares represent, on an undiluted basis, 11% of Helix`s current issued and outstanding shares before giving effect to this transaction. The Helix shares issued will be issued at a deemed price of $2.20 per share, and will have a contractual hold period of 12 months from closing, the first four months of which will run concurrently with applicable regulatory 4 month hold periods. The interest in Sensium being acquired is 28.8%, following the exercise by certain minority shareholders of stock options and warrants.

The remaining stock options and warrants to purchase up to 440,000 Sensium shares at $1.00 per share held by the minority Sensium shareholders will be cancelled, and instead those shareholders who are also employees of or consultants to Sensium, will be issued options to purchase up to 390,000 common shares of Helix, at $5.00 per share, expiring in January and March, 2006. These options will not form part of Helix`s 2000 Stock Option Plan, but will be granted outside the Plan.

Two of the Sensium minority shareholders who will be selling their shares to Helix are directors of Sensium, and will be resigning as such directors on closing of this transaction. On closing, these Sensium directors will receive a total of 485,000 common shares of Helix in exchange for their 485,000 shares of Sensium. One of the Sensium directors, who is also on Sensium`s Scientific Advisory Board, will also receive options to purchase 140,000 common shares of Helix at $5.00 per share, expiring March 31, 2006, and his 140,000 Sensium options will be cancelled.

In addition, certain directors, officers and employees of Helix are also directors, officers or employees of Sensium and hold options to purchase up to 600,000 shares of Sensium at $1.00 per share, which they have agreed to cancel. These individuals will be granted options, pursuant to Helix`s 2000 Option Plan, to purchase 600,000 common shares of Helix at $5.00 per share, expiring March 31, 2006.

This transaction was unanimously approved by Helix`s board of directors. At the instruction of the board, management prepared an internal assessment of the fair value of the Sensium technology. No formal valuations were obtained.

Ongoing research has demonstrated the potential of Sensium`s technology for drug discovery purposes. In view of the technology`s growing importance to Helix`s drug discovery and development program, Helix has determined that it is in the best interest of the Company to acquire the minority interest in Sensium.

Closing of this transaction is expected to occur on or about December 9, 2002. Helix believes that a closing within a period of less than 21 days from the date hereof is reasonable as the related parties acquiring Helix shares or options in this transaction constitute only a portion of the entire transaction and such parties are participating in this transaction on the same terms as the unrelated parties. In addition, the general terms of this transaction were previously announced on October 16, 2002.

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements, which statements can be identified by the use of forward-looking terminology such as "proposes", "may", "will", "expect", "anticipate", "estimate", "predict", "plans", or "continue" or the negative thereof or any other variations thereon or comparable terminology referring to future events or results. The Company`s actual results could differ materially form those anticipated in these forward-looking statements as a result of numerous factors, including the need for regulatory approval which may not be obtained, risk of technical obsolescence, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the need for performance of contractual obligations by third parties, and the fact that the closing of the Sensium transact
ion described herein may not occur as anticipated, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. See the Company`s reports filed with the Toronto Stock Exchange and the Ontario Securities Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.


--------------------------------------------------------------------------------
Contact:

Helix BioPharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



--------------------------------------------------------------------------------

[Imperio]

Hi Snaker,

danke Dir fürs reinstellen der Infos!

Habe jetzt alles von Helix gelesen und finde ein Investement aufgrund der Fakten sehr interessant.

Nur erkläre mir doch mal folgendes:

Wie soll denn ein Kursziel von 10,01 CAD in 25 Tagen realisiert werden. Das ist doch unseriös, wenn gleichzeitig BB und sein link auf first Berlin ein Kursziel in 6-12 Monaten von 6-7 CAD angibt.

Für eine Antwort wäre ich dankbar!

Viele Grüsse

[Bombenleger]

Helix Interferon-alpha Cream Enters Next Phase Of
Development
Tuesday December 17, 9:13 am ET

AURORA, ONTARIO--

Topical Therapeutic to Complement Preventative Vaccines

John Docherty, Vice President of Corporate Development, today announced that Helix`s
Interferon-alpha Cream development program is prepared to advance to the cGMP production
phase, for the manufacture of product for clinical studies planned for 2003. To facilitate this,
Helix has signed a contract services agreement with an established Canadian pharmaceutical
manufacturing facility, WellSpring Pharmaceutical Canada Corporation.

Helix`s Interferon-alpha Cream is being
developed to principally treat infection
and disease caused by the Human
Papilloma Virus (HPV). It has been
estimated that as many as 40 million
persons are currently infected with this
sexually transmitted virus, which
continues to grow at an alarming rate of
5 million new cases annually in the US
alone.

The present treatment of HPV-induced
lesions with interferon-alpha involves
regular intralesional injections.
Interferon-alpha is an immune system
modulator that is administered by
repeated injections for the treatment of a
number of diseases, including HPV
infections. Treatment by this method is painful and limited to visible, external lesions. In
comparison, Helix`s Interferon-alpha Cream will be relatively painless and is also being
developed to treat non-visible lesions. Other current treatments for HPV include caustic
chemical preparations and/or invasive surgical procedures. These treatments have limited
effectiveness and are painful for the patient.

Other companies have recognized the need for new treatment options for HPV, and some are
developing potential HPV vaccines as preventative measures. These vaccines, which are only
at the very early stages of clinical development, would be restricted to preventing infection in
persons not yet exposed to the virus through sexual activity. Given the pervasiveness of this
virus, it is doubtful that HPV will ever be eradicated by vaccination alone.

"Furthermore, there are concerns about the effectiveness and length of protection that these
vaccines would actually provide, presenting a real possibility that future generations will still be
infected by HPV later in life despite vaccination during youth", said John Docherty, Vice
President of Corporate Development. "For this reason, many experts believe that there will
always be a very important place in medicine for continued surveillance and treatment
management options, such as Helix`s therapeutic cream." As a result, Helix`s Interferon-alpha
Cream is expected to offer treatment not only to the generations of men and women in the
world today who are already infected, but also to future generations. Thus, Helix feels that its
Interferon-alpha Cream will be complementary to any future vaccines that may come to market
for HPV-induced infections.

Wellspring Pharmaceutical Canada will manufacture the clinical supplies of the Interferon-alpha
cream in its plant in Oakville, a suburb of Toronto. The plant conforms to current Good
Manufacturing Practices as required by regulatory authorities in North America and Europe,
and currently produces more than 20 formulations of both prescription and OTC drugs.

The Toronto and Frankfurt Stock Exchanges have not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this News Release. This press
release contains forward-looking statements concerning anticipated developments in the
Company`s business, including the development and potential success of its Interferon-alpha
Cream, and other information in future periods. These forward-looking statements can be
identified by the use of forward-looking terminology, such as, "planned", "may", "being
developed", "are developing", "believe", "possibility", "expected" and similar expressions or
variations thereon, or statements that events, conditions or results "will," "may," "would",
"could", or "should" occur or be achieved. Forward-looking statements are statements about
the future and are inherently uncertain, and actual achievements of the Company and other
results and occurrences may differ materially from those reflected in the forward-looking state
ments due to a variety of risks, uncertainties and other factors, including, without limitation,
uncertainty as to whether the Company`s clinical trials of its Interferon-alpha Cream will occur
as presently planned or at all; the need for regulatory approval prior to commencement of
clinical trials, which approval is not assured; uncertainty as to the outcome of any clinical trials;
the need for performance by the Company`s suppliers, including its third party contract service
providers; uncertainty as to the effectiveness of the Company`s Interferon-alpha Cream, whether
in treating lesions, non-visible lesions or otherwise; uncertainty as to whether any vaccines will
be developed and marketed, or if developed and marketed, whether they will be effective in
eradicating HPV infections; uncertainty as to whether the Company`s Interferon-alpha Cream
will be complementary to HPV vaccines; uncertainty as to market acceptance of the
Company`s products; and other risks and uncertai
nties identified in this press release and other regulatory filings. The Company`s forward-looking
statements are based on the beliefs, expectations and opinions of management on the date the
statements are made, and the Company does not assume any obligation to update
forward-looking statements if circumstances or management`s beliefs, expectations or opinions
should change. For the reasons set forth above, investors should not place undue reliance on
forward-looking statements. See also the Company`s reports filed with the Toronto Stock
Exchange, and the Ontario, B.C. and Manitoba Securities Commissions from time to time for
other cautionary statements identifying important factors with respect to the Company`s
forward-looking statements. The Company does not assume any obligation to update any
forward-looking statement contained herein.

Page 1 of 2

Contact:

Helix BioPharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



Source: Helix BioPharma Corp.

[zentrader]

@all,

gutes erstes Quartal von Helix Biopharma:
http://biz.yahoo.com/ccn/021220/cd379cf9757a56b1e68a407e3948…

ciao,
zentrader
http://www.zentrader.de

[oasenfred]

@zentrader

Kennst Du diese Studie schon?

http://www.mintsites.de/firstberlin/research/pdf/helix_dec_2…

[tyx]

Kennt Ihr diese Seite schon ?
http://www.myResearch.de/918846

[zentrader]

@all,

normalerweise gibt`s kaum Umsätze und heute gleich an allen deutschen Börsenplätzen Verkäufe - weiß jemand etwas? Stehen wieder Warant-Einlösungen etc. bevor...?

ciao,
zentrader
http://www.zentrader.de

[Bombenleger]

Major Heterodimer Biochip Patent Granted To Helix
Tuesday February 4, 3:38 pm ET

AURORA, ONTARIO--Helix has added to its portfolio of intellectual property with the granting of
a significant US patent for the use of its Heterodimer Protein Technology in micro-array
applications. This newly issued patent incorporates several detection modalities including
optical, electro-chemical and piezo-electric systems.

Helix is using its patented Heterodimer
Protein Technology and Molecular
Sensing Technology in the development
of biopharmaceutical research-based
tools, including protein chips or
"biochips". These biochips are being
designed for use by biopharmaceutical
research companies, institutions and
organizations in the study of protein
interactions for the purpose of
discovering and developing
biopharmaceuticals and diagnostics.

Biochips are expected to become an
integral part of biopharmaceutical
research as scientists increasingly
incorporate genomics and proteomics
based techniques in the drug discovery
process. Currently, more than US$ 50 Billion is spent annually on pharmaceutical research and
development.

As the adoption of genomic and proteomic techniques increases, the percentage of
expenditures by biopharmaceutical research companies, institutions and organizations on
genomic and proteomic based research is expected to grow dramatically. It has been
estimated that by 2005 the market for protein and genomic biochips and related consumables
will exceed US$5 Billion annually.

Helix is continuing the development of its protein-based tools and biochips through its
collaborations with the Centre Hospitalier Universitaire de Québec (CHUQ) in its study of
nuclear receptor proteins; through ongoing work with the Protein Engineering Centres of
Excellence (PENCE) and the University of Alberta; and through its agreement with the
Biotechnology Research Institute of the National Research Council of Canada (BRI-NRC).

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility
for the adequacy or accuracy of the content of this News Release. This press release contains
forward-looking statements concerning anticipated developments in the Company`s business,
including, without limitation, statements concerning the Company`s biochip currently in
development, the potential uses thereof, and estimates and expectations concerning the
market for protein and genomic biochips and related consumables. These forward-looking
statements can be identified by the use of forward-looking terminology, such as, "are being",
"for", "expected", "estimated" and similar expressions or variations thereon. Forward-looking
statements are statements about the future and are inherently uncertain, and actual
achievements of the Company and other results and occurrences may differ materially from
those reflected in the forward-looking statements due to a variety of risks, uncertainties
and other factors, including, without limitation, the risk of technical obsolescence,
intellectual property risks, research and development risks, marketing/manufacturing risks,
partnership/strategic alliance risks (including the need for performance and cooperation by the
Company`s collaborators, CHUQ, PENCE and BRI-NRC), and the effect of competition,
exchange rate fluctuations, and government regulation. These and other factors are described
in detail in the Company`s Annual Information Form, news releases and other filings with the
Canadian securities regulatory authorities. The Company`s forward-looking statements are
based on the beliefs, expectations and opinions of management on the date the statements are
made, and the Company does not assume any obligation to update forward-looking statements
if circumstances or management`s beliefs, expectations or opinions should change. For the
reasons set forth above, investors should not place undue reliance on forward-looking
statements.

Contact:

Helix BioPharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



Source: Helix BioPharma Corp.

[Bombenleger]

Helix BioPharma: Revenue Up In Second Quarter
Friday March 28, 3:26 pm ET

AURORA, ONTARIO--For the second consecutive quarter, Helix experienced a significant increase
in total revenues, increasing by 29% for the three months ended January 31, 2003 over the same
period in fiscal 2002. The increase was driven by a 49% rise in pharmaceutical sales, due largely to
the success of ORTHOVISC®, a treatment for osteoarthritis of the knee. Royalty revenue from the
sales of Klean-Prep(TM) also increased by 5% in the quarter over the same period in fiscal 2002.

Research and development expenditures decreased slightly by 5% to $566,000 in the second
quarter of fiscal 2003 from the same period last year. The Company has made continued progress
in its Interferon-alpha Cream development program with the procurement and validation of major
processing equipment necessary for the scale-up manufacture of clinical supplies to be produced at
WellSpring Pharmaceutical Canada Corporation`s pharmaceutical manufacturing facility.

Marketing and administration expenses declined by $261,000 to $538,000 in the current quarter,
down from $799,000 for the same period in the previous year.

For the second quarter ended January 31, 2003, Helix incurred a loss of $637,000 ($0.03 per share)
versus a loss of $1,014,000 ($0.05 per share) for the same period in fiscal 2002.

The Company`s cash, cash equivalents and short-term investments were down slightly to $11.1
million this quarter from $11.6 million at year-end, July 31, 2002.

During the quarter, Helix issued 2,430,000 common shares and also issued options to purchase
990,000 common shares at $5.00 per share, expiring in January and March 2006, to acquire the
25% minority interest in Sensium not then owned by Helix, which represents a total purchase price
of $5.96 million. Sensium is developing new drug discovery tools, based on its patented protein
technologies, for the discovery and development of biopharmaceuticals and diagnostics.

The full interim financial statements and accompanying Management`s Discussion and Analysis are
available on SEDAR (www.sedar.com).

The consolidated interim financial statements are summarized below:

January 31 July 31
2003 2002
(unaudited)
Interim Consolidated Balance Sheets ($`000)
Assets
Cash and cash equivalents 10,255 3,054
Short-term investments 848 8,568
Other current assets 1,050 993
Non-current assets 6,750 1,715
----------------
Total Assets 18,903 14,330
----------------
----------------
Liabilities and Equity
Current liabilities 702 1,001
Non-current liabilities 91 478
Share capital 38,038 31,706
Deficit (19,928) (18,855)
------------------
Total Liabilities and Equity 18,903 14,330
------------------
------------------

3 months ended 6 months ended
January 31 January 31
2003 2002 2003 2002
Unaudited Interim Consolidated
Statements of Operations
($`000 except per share amounts)
Total Revenue 549 424 1,112 800
Expenses (excluding R&D) 695 934 1,502 1,691
Research and development 566 594 1,242 1,259
------------------------------------
(712) (1,104) (1,632) (2,150)
Other income 75 90 559 247
------------------------------------
Loss for the period (637) (1,014) (1,073) (1,903)
------------------------------------
------------------------------------
Loss per share - basic and fully
diluted (0.03) (0.05) (0.05) (0.09)
------------------------------------
------------------------------------

3 months ended 6 months ended
January 31 January 31
2003 2002 2003 2002
Unaudited Interim Consolidated
Statements of Cash Flows
($`000)
Cash (used in) operating
activities (1,236) (621) (1,678) (1,497)
Cash (used in)
provided by financing activities (12) (11) (21) (21)
Cash (used in) provided by
investing activities 365 3,448 8,900 10,240
-------------------------------------
(Decrease) increase in cash
and cash equivalents (883) 2,816 7,201 8,722
Cash and cash
equivalents-beginning of period 11,138 9,768 3,054 3,862
-------------------------------------
Cash and cash equivalents-end
of period 10,255 12,584 10,255 12,584
-------------------------------------
-------------------------------------

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for
the adequacy or accuracy of the content of this News Release. This News Release may contain
certain forward-looking statements, which statements can be identified by the use of forward-looking
terminology such as "may", "will", "expect", "anticipate", "estimate", "predict", "plans", or
"continue" or the negative thereof or any other variations thereon or comparable terminology referring
to future events or results. Forward looking statements are statements about the future and are
inherently uncertain, and the Company`s actual results could differ materially from those anticipated
in these forward-looking statements as a result of numerous factors, including without limitation, the
risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a
timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be
assu
red, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the
effect of competition, uncertainty of the size and existence of a market opportunity for the
Company`s products, the Company`s need for additional future capital, which may not be available in
a timely manner or at all, as well as a description of other risks and uncertainties affecting the
Company and its business, as contained in news releases and filings with the Canadian Securities
Regulatory Authorities, any of which could cause actual results to vary materially from current
results or the Company`s anticipated

future results. Forward-looking statements are based on the beliefs, opinions and expectations of
the Company`s management at the time they are made, and the Company does not assume any
obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other
circumstances should change.

Contact:

Helix BioPharma Corp.
Gerald Salvati, Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



Source: Helix BioPharma Corp.

[Mr.A]

Hohe Umsätze in der letzten Woche.

Der Kurs hält sich auch verdammt gut. Wenn die Kriegswirren endlich vorüber sind solls auch wieder aufwärts gehen.

Aus "stets gut informierten, unternehmsnahen Kreisen" weiß ich von institutionellen Anlegrern, die in den Startlöchern stehen.

So lange heißt es wie schon so lange abwarten und Tee trinken ...

Also bis bald

[BB.]

Aber zuerst einmal scheint einer sein Depot bezüglich Helix komplett auflösen zu wollen (müssen).
Wollen mal hoffen, dass der Kurs das wegsteckt.
Ich glaube auch, dass es bald wieder aufwärts mit Helix (den Kurs meine ich).
Irgend wann muss doch mal jemand merken, dass die Zahlen von denen kontinuierlich besser werden und dass die von Seiten der Firmenentwicklung her keinen Einbruch haben.
BB

[tellmemore]

Was geht denn heute ab. Nachdem es Wochenlang relativ ruhig war,
sind bis jetzt schon über 70000 in Deutschland gehandelt worden
und über 340000 in Toronto. Eine Order ging sogar über 150000
Stück. Leider hat das den Kurs nicht großartig beeinflusst.
Weiss einer was da los ist oder spinnt nur meine Anzeige ???

Gruss
tmm

[BB.]

Nein, Deine Anzeige spinnt nicht.
Ich frage mich nur, was das für Deppen sind, die bei diesem niedrigen Kurs so große Stückzahlen verkaufen.
Es kann niemanden geben, der bei dem Kurs und bei den Stückzahlen einen Gewinn macht.
Selbst die Käufer, die vor ein paar Jahren für unter diesem Kurs gekauft haben, hätten genug Möglichkeiten gehabt, bei einem wesentlich höheren Kurs zu verkaufen.
Das verstehe wer wolle.
BB.

[Mr.A]

Wird doch!

Umsätze wieder ok. und Kurs steigt.

Jetzt nur nicht gleich aussteigen! In dem Laden ist richtig Musik drin.

Auf ein todschickes Jahr ...

[BB.]

Na hoffentlich nehmen sich Deine Worte möglichst viele Leute zu Herzen.
BB

[Bombenleger]

April 9, 2003

Helix BioPharma Corp.:Two New European Biochip Patents Granted

AURORA, ONTARIO--Two additional patents have been granted to Helix by the European Patent Office for its Molecular Sensing Technology and Heterodimer Protein Technology. These patents complement two previously announced United States patents granted to Helix.

Helix is using its patented Heterodimer Protein Technology and Molecular Sensing Technology in the development of biopharmaceutical research-based tools, including protein chips or "biochips". These biochips are being designed for use by biopharmaceutical research companies, institutions and organizations in the study of protein interactions for the purpose of discovering and developing biopharmaceuticals and diagnostics.

Helix is collaborating in development of its protein-based tools and biochips with the Centre Hospitalier Universitaire du Quebec (CHUQ) in its study of nuclear receptor proteins; through ongoing work with the Protein Engineering Network of Centres of Excellence (PENCE) and the University of Alberta; and through its agreement with the Biotechnology Research Institute of the National Research Council of Canada (BRI-NRC).

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the development and future use of Helix`s biopharmaceutical research-based tools, including protein chips or "biochips", which statements can be identified by the use of forward-looking terminology such as "are expected", "are being designed for use", "is using", "is collaborating", "ongoing", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, research & development risks, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances should change.



- 30 -

FOR FURTHER INFORMATION PLEASE CONTACT :

Helix Biopharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]

[BB.]

Dieses neue Patent wirkt sich ja mal wieder richtig toll auf den Kurs aus.
Schon schade, dass jedes Mal bei guten Nachrichten so viele Stücke verkauft werden.
Sonst wäre der Kurs sicherlich schon ganz wo anders.
BB

[Bombenleger]

Helix BioPharma Corp.: Third Consecutive Revenue Increase
Friday June 27, 12:30 pm ET

AURORA, ONTARIO--Helix BioPharma Corp. experienced its third consecutive quarter of increasing revenues with a 47% increase for the quarter over the same period in fiscal 2002. This $184,000 increase was driven by continued growth in pharmaceutical sales, due largely to the success of ORTHOVISC®, a treatment for osteoarthritis of the knee. Royalty revenue of $268,000 from sales of Klean-Prep(TM) also increased by 66% in the third quarter over the third quarter of fiscal 2002 as a result of continued sales success in Europe.

Research and development expenses for the third quarter ended April 30, 2003 increased by $203,000 (37%) to $751,000, as compared to the same quarter in fiscal 2002, due to an increase in spending on analytical and contract manufacturing activities for the Interferon-alpha cream program, and on the development of Sensium`s platform Heterodimer Protein Technology.

Marketing, general and administration expenses increased by $187,000 in the quarter ended April 30, 2003 to $724,000 from $537,000, as compared with the same three-month period in fiscal 2002. This increase reflects costs incurred for expanding the sales force, initiating programs for sales of ORTHOVISC®, and for corporate development activities related to the Company`s subsidiaries. Management continues to monitor expenditures in this area.

For the three-month period ended April 30, 2003, Helix incurred a loss of $1,053,000 ($0.04 per share) versus a loss of $1,044,000 ($0.04 per share) for the same period in fiscal 2002, an increase of $9,000 (1%).

Cash, cash equivalents and short-term investments as at April 30, 2003 totaled $9,895,000, a decline of $1,727,000 from the July 31, 2002 total of such balances of $11,622,000.

The full interim financial statements and accompanying Management`s Discussion and Analysis are available on SEDAR (www.sedar.com).

The consolidated interim financial statements are summarized below:

April 30 July 31
2003 2002
(unaudited)

Interim Consolidated Balance Sheets ($`000)

Assets
Cash and cash equivalents 3,031 3,054
Short-term investments 6,864 8,568
Other current assets 955 993
Non-current assets 7,120 1,715
-----------------------------------------------------------------------

Total Assets 17,970 14,330
-----------------------------------------------------------------------
-----------------------------------------------------------------------

Liabilities and Equity
Current liabilities 831 1,001
Non-current liabilities 82 478
Share capital 38,038 31,706
Deficit (20,981) (18,855)
-----------------------------------------------------------------------

Total Liabilities and Equity 17,970 14,330
-----------------------------------------------------------------------
-----------------------------------------------------------------------


3 months ended 9 months ended
April 30 April 30
2003 2002 2003 2002
Unaudited Interim Consolidated
Statements of Operations
($`000 except per share amounts)

Total Revenue 574 390 1,686 1,190

Expenses (excluding R&D) 918 948 2,420 2,639
Research and development 751 548 1,993 1,807
-----------------------------------------------------------------------
(1,095) (1,106) (2,727) (3,256)
Other income 42 62 601 309
-----------------------------------------------------------------------

Loss for the period (1,053) (1,044) (2,126) (2,947)
-----------------------------------------------------------------------
-----------------------------------------------------------------------

Loss per share - basic and
fully diluted (0.04) (0.04) (0.09) (0.13)
-----------------------------------------------------------------------
-----------------------------------------------------------------------



3 months ended 9 months ended
April 30 April 30
2003 2002 2003 2002
Unaudited Interim Consolidated
Statements of Cash Flows
($`000)

Cash (used in) operating activities (755) (834) (2,433) (2,331)
Cash (used in) provided by financing
activities (12) (11) (33) (32)
Cash (used in) provided by investing
activities (6,457) (8,172) 2,443 2,068
-----------------------------------------------------------------------
(Decrease) increase in cash and cash
equivalents (7,224) (9,017) (23) (295)
Cash and cash equivalents-beginning
of period 10,255 12,584 3,054 3,862
-----------------------------------------------------------------------

Cash and cash equivalents-end of
period 3,031 3,567 3,031 3,567
-----------------------------------------------------------------------
-----------------------------------------------------------------------


Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release may contain certain forward-looking statements, which statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "anticipate", "estimate", "predict", "plans", or "continue" or the negative thereof or any other variations thereon or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances should change.
Contact:

Helix BioPharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]


Source: Helix BioPharma Corp.

[MicroSnake]

Sieht doch garnicht so schlecht aus ........

[Bombenleger]

Helix BioPharma Corp.: Results Of Prostate Cancer Research To Be Presented
Friday August 1, 3:50 pm ET

AURORA, ONTARIO--In presentations at the 2003 Federation of American Societies of Experimental Biology (FASEB) Summer Research Conference in Tucson, Arizona, Drs. M. V. Govindan and N. Warriar of the Centre Hospitalier Universitaire de Quebec are announcing the results of Helix`s research conducted to date to characterize proteins related to prostate cancer.

ADVERTISEMENT
Researchers have identified two novel proteins that affect the life cycle of prostate cancer cells.

These discoveries are significant for the potential development of new treatments and diagnostic tests for prostate cancer. Prostate cancer is the leading cancer in men, with approximately 200,000 new cases diagnosed annually in North America, and kills more than 40,000 North American men each year.

Helix continues to work with Centre Hospitalier Universitaire de Quebec and the Biotechnology Research Institute of the National Research Council of Canada to identify drug targets with the objective of developing new pharmaceuticals against prostate and breast cancers.

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the development and future use of Helix`s biopharmaceutical research based tools, including protein chips or "biochips", and the development and potential success of its Interferon-alpha Cream and other information in future periods. Forward-looking statements can be identified by the use of forward-looking terminology such as "are expected", "are being designed for use", "is using", "is collaborating", "ongoing", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, research & development risks, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are mad e, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances should change.
Contact:

Gerald Salvati, Investor Relations
Helix BioPharma Corp.
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]


Source: Helix BioPharma Corp.

[Bombenleger]

Helix BioPharma Corp.: Corporate Update
Monday August 18, 12:26 pm ET


AURORA, ONTARIO--There has been no material change in the Company`s affairs since its last press release that would explain the recent activity in the market for its common shares.
Interferon-Alpha Cream

ADVERTISEMENT


Helix is continuing to make steady progress in the development of its Interferon-alpha cream for the treatment of diseases caused by Human Papilloma Virus ("HPV"), primarily genital warts and cervical dysplasia, the precursor to cervical cancer. The Company is currently evaluating various clinical trial sites in Europe and North America. As previously announced, clinical trials are planned for 2004.

Cancer Research

Helix`s cancer research continues to characterize proteins related to prostate cancer and to identify drug targets with the objective of developing new pharmaceuticals against prostate and breast cancers.

BioChips

Helix is using its Heterodimer Protein Technology to develop biopharmaceutical research tools, including protein chips or "biochips", for use in high throughput screening in the drug development process.

Investor Relations

Since June, the Company has made a number of presentations in Europe and North America, including presentations made in Germany at the facilities of the Frankfurt Stock Exchange, the Munich Stock Exchange, the Stuttgart Stock Exchange, as well as in Berlin and Hamburg.

Corporate Finance

A number of investment banks have recently approached the Company to obtain further information regarding Helix`s corporate development and to discuss the possibilities of further financings for the Company. Helix is currently considering these approaches, but, to date, has not made any commitments.

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the development and future use of Helix`s biopharmaceutical research based tools, including protein chips or "biochips", and the development and potential success of its Interferon-alpha Cream and other information in future periods. Forward-looking statements can be identified by the use of forward-looking terminology such as "are expected", "are being designed for use", "is using", "is collaborating", "ongoing", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, research & development risks, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are ma de, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances should change.


--------------------------------------------------------------------------------
Contact:

Helix BioPharma Corp.
Gerald Salvati,
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



--------------------------------------------------------------------------------
Source: Helix BioPharma Corp.

[Bombenleger]

Helix Completes Toxicology Studies
Thursday August 28, 5:07 pm ET


AURORA, ONTARIO--Helix continues to advance the development of its interferon-alpha cream with the completion of pre-clinical toxicology studies. Helix believes that the results of these studies are sufficient to satisfy the regulatory toxicology requirements for Helix`s clinical trials, planned for 2004.
ADVERTISEMENT


"We are pleased that Helix has reached this significant milestone, which is one of the key requirements necessary to allow us to commence our clinical program," said John Docherty, Helix`s Vice-President - Corporate Development.

Helix is developing its interferon-alpha cream for the treatment of diseases caused by Human Papilloma Virus ("HPV"), primarily genital warts and cervical dysplasia, the precursor to cervical cancer.

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the development and future use of Helix`s biopharmaceutical products, including the development and potential success of its Interferon-alpha Cream and other information in future periods. Forward-looking statements can be identified by the use of forward-looking terminology such as "continues", "development", "believes", "planned", or the negative thereof or any other variations thereon or comparable terminology referring to future dates, events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the risk that the toxicology studies are not sufficient to satisfy the regulatory toxicology requirements for Helix`s clinical trials; the risk that other key requirements may not be met in order to commence the clinical program; the risk that the clinical program cannot commence as planned in 2004; research & development risks, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actua l results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances should change.


--------------------------------------------------------------------------------
Contact:

Helix BioPharma Corp.
Gerald Salvati
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]



--------------------------------------------------------------------------------
Source: Helix BioPharma Corp.

[Snaker]

Informationsveranstaltung von Helix in Maastricht !!!
Anbei der Termin zur Veranstaltung in Maastricht,
bei interesse bitte anmelden unter :
www.helixbiopharma.com - oder - welcome.to/hbp-biotech.

Termin : 25.09.2003, 19.00 Uhr

Ort : Hotel Van der Valk Maastricht (Nijverheidsweg 35, 6227 AL Maastricht

Euer snaker

Und immer schön die Aktien halten, denn
hast du Helix im Depot ...........

[Diva]

.... war ich nicht nett ... mit den 1500 zu 3,50 ...

cu at 5,-

Diva

[Pianocashman]

Hi

Hoffentlich kein Betrug? Der Kursanstieg ist schon beeindruckend, aber ich habe meine Zweifel bei OTC-Werten. Am ende wird der kleine Privatanleger wieder verarscht...es gab in der Vergangenheit zuviele ähnlich gelagerte Fälle.

Piano

[Moneymaker]

Quelle: TRADERS BRIEFING / wallstreet:online AG


11.09.2003 20:30:23 Uhr
Helix Biopharma - Bedeutende Meldung steht scheinbar kurz bevor / ISIN: CA4229101098

Die kanadische Helix ist eine integrierte Arzneimittelfirma, die sich auf die Entwicklung
und Vermarktung von neuen Arzneimitteln spezialisiert hat.

Gerüchte verdichten sich, dass die Gesellschaft in Kürze eine wichtige Mitteilung publizieren wird. Aufgrund der Bedeutung dieser Meldung könnte es zu einer Handels-aussetzung kommen. Eine deutliche Kurssteigerung sollte folgen.

Wir rechnen mit der Meldung am Anfang nächster Woche. Der Kurs sollte Richtung 5 Euro marschieren.

[Moneymaker]

Die Meldung (siehe vorheriges Posting) wurde erst um 20.30 Uhr abgesetzt. Der Kursanstieg wurde also nicht von der WO-Meldung verursacht. Das stimmt mich zuversichtlich, dass da doch was dran ist.

Der Wert scheint hier auch noch nicht entdeckt worden zu sein.

Mal schaun, ob wir heute schon die 5,00 Euro sehen?

[Neger69]

Ich traue meinen Augen nicht!

Helix im roten w:o Laufband.

[Diva]

.... ich glaube, ich traue meinen Augen nicht !!!!!!!!!

das nenn ich feeling ....

cu at 7,-

Diva

[Bombenleger]

Helix BioPharma Corp.: Positive Results with Potential Anti-Cancer Compound
Friday September 12, 8:50 am ET


AURORA, ONTARIO--Helix `s new drug candidate, DOS47, has been shown to successfully treat human breast cancer tumours in a controlled experiment with mice.
All mice that received DOS47 responded within 48 hours of administration, showing no trace of any remaining living cancerous tissue. Tumour growth continued in control animals that did not receive DOS47.

No perceptible adverse effects were observed.

Helix is planning to study the effectiveness of DOS47 against several types of cancers.

"While we are optimistic about the prospects for this compound," Dr. Donald Segal, Executive Vice President of Helix, cautions, "these animal results are preliminary and just the first step in the complex and lengthy development process of a human cancer therapeutic."

About breast cancer

Breast cancer is a leading cause of death among women. According to the American Cancer Society, there is a one in eight chance that a woman will develop breast cancer in her lifetime.

Helix BioPharma trades on the TSE and FSE under the symbol "HBP"

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding Helix`s plans to study the effectiveness of DOS47 against several types of cancers and the possibility of developing a human cancer therapeutic. Forward-looking statements can be identified by the use of forward-looking terminology such as "planning", "optimistic", "prospects", "process", or variations thereon or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and the Company`s actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, research & development risks, the risk of technical obsolescence, the need for regulatory approval, which may not be obtained in a timely matter or at all, the need for clinical trials, the occurrence and success of which cannot be assured, intellectual property risks, marketing/manufacturing and partnership/strategic alliance risks, the effect of competition, uncertainty of the size and existence of a market opportunity for the Company`s products, the Company`s need for additional future capital, which may not be available in a timely manner or at all, as well as a description of other risks and uncertainties affecting the Company and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or the Company`s anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of the Company`s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statement if those beliefs, opinions or expectations, or other circumstances shou ld change.


--------------------------------------------------------------------------------
Contact:

Helix BioPharma Corp.
Gerald Salvati,
Investor Relations
Phone: [phone] ext. 232
Fax: [phone]
[e-mail]
www.helixbiophara.com



--------------------------------------------------------------------------------
Source: Helix BioPharma Corp.